Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5272196
Max Phase: Preclinical
Molecular Formula: C23H17F4N3
Molecular Weight: 411.40
Associated Items:
ID: ALA5272196
Max Phase: Preclinical
Molecular Formula: C23H17F4N3
Molecular Weight: 411.40
Associated Items:
Canonical SMILES: Fc1ccc2ncnc(NCCc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c2c1
Standard InChI: InChI=1S/C23H17F4N3/c24-19-9-10-21-20(13-19)22(30-14-29-21)28-12-11-15-1-3-16(4-2-15)17-5-7-18(8-6-17)23(25,26)27/h1-10,13-14H,11-12H2,(H,28,29,30)
Standard InChI Key: RJDQMWRGXYLSKP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 411.40 | Molecular Weight (Monoisotopic): 411.1359 | AlogP: 6.11 | #Rotatable Bonds: 5 |
Polar Surface Area: 37.81 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 3.99 | CX LogP: 6.17 | CX LogD: 6.17 |
Aromatic Rings: 4 | Heavy Atoms: 30 | QED Weighted: 0.40 | Np Likeness Score: -1.22 |
1. Elsocht M, Giron P, De Grève J, Ballet S.. (2023) Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells., 79 [PMID:36410591] [10.1016/j.bmcl.2022.129066] |
Source(1):